KEY TAKEAWAYS
- The study aimed to investigate the prognostic significance of cuproptosis and ICD in DLBCL pts.
- Researchers noticed significant insights into the roles of cuproptosis and ICD in DLBCL, paving the way for personalized treatment strategies.
Diffuse large B-cell lymphoma (DLBCL), the prevalent form of non-Hodgkin lymphoma, exhibits substantial heterogeneity worldwide. Cuproptosis and immunogenic cell death (ICD) have emerged as pivotal factors in the progression of this lymphoma. However, the current understanding of these phenomena in DLBCL remains limited. Nana Wang and her team focused on unraveling the intricacies of cuproptosis and ICD and their collective impact on DLBCL.
Researchers performed an inclusive analysis utilizing Pearson’s correlation to identify long non-coding RNAs (lncRNAs) associated with cuproptosis and ICD. Prognostic biomarker identification and model construction involved univariate Cox regression, LASSO Cox regression, and multivariate Cox regression. The predictive capability of the risk model was assessed through Kaplan-Meier and time-dependent ROC analysis.
This study also included analysis and comparison of immune infiltration and drug sensitivity. Additionally, RT-qPCR was employed to validate lncRNA expression related to cuproptosis and ICD in DLBCL cell lines.
Four prognosis-related lncRNAs (ANKRD10-IT1, HOXB-AS1, LINC00520, and LINC01165) were identified, demonstrating correlations with cuproptosis and ICD in DLBCL. The constructed model exhibited robust and independent predictive capabilities for DLBCL patients (pts) prognostic outcomes. Notably, the high- and low-risk groups observed a significant difference in immune infiltration and drug sensitivity.
The study concluded that the insights gained significantly enhance the understanding of cuproptosis and ICD in DLBCL, providing potential novel perspectives and knowledge for the personalized and precise treatment of individuals with DLBCL.
Source: https://pubmed.ncbi.nlm.nih.gov/38284893/
Wang N, Shi S, Li M, et al. (2023). “Development and validation of a combined cuproptosis and immunogenic cell death prognostic model for diffuse large B-cell lymphoma.” Aging (Albany NY). 2024 Jan 26;16(2):1218-1236. doi: 10.18632/aging.205399. Epub 2024 Jan 26. PMID: 38284893.
